From Financial Modeling Prep: 2024-11-11 07:48:00

BofA Securities analysts adjusted Omnicell’s price target from $57 to $54, maintaining a Neutral rating. The latest survey projects 2025 pharmacy IT budget growth of 4%, slightly lower than in 2024. Positive capital expenditure trends and new product offerings support potential growth, but long-term revenue trajectory remains uncertain.

Despite a strong position in the pharmacy automation market, Omnicell’s future growth is clouded by limited visibility on the product revenue ramp.



Read more at Financial Modeling Prep:: Omnicell Target Price Lowered Amid Uncertain Growt…